Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actinium Pharmaceuticals

1.83
+0.14008.28%
Post-market: 1.840.0097+0.53%19:47 EDT
Volume:336.47K
Turnover:604.96K
Market Cap:57.09M
PE:-1.24
High:1.85
Open:1.69
Low:1.65
Close:1.69
Loading ...

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

TIPRANKS
·
20 May

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
13 May

Actinium Pharmaceuticals Inc - Initial Clinical Data Expected in Second Half of 2025

THOMSON REUTERS
·
06 May

Actinium Announces Enrollment of First Patient in the Iomab-Act Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

THOMSON REUTERS
·
06 May

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

PR Newswire
·
28 Apr

Levi & Korsinsky LLP Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline

TIPRANKS
·
03 Apr

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Actinium Pharmaceuticals: Strategic Advancements and Financial Stability Signal Undervalued Opportunity

TIPRANKS
·
29 Mar

Actinium announces positive ATNM-400 results in prostate cancer

TIPRANKS
·
27 Mar

BRIEF-Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Reuters
·
27 Mar

Actinium Pharmaceuticals Inc -99.8% Tumor Growth Inhibition Achieved With a Single Dose of Atnm-400 in Preclinical Prostate Cancer Models

THOMSON REUTERS
·
27 Mar

Actinium Pharmaceuticals Announces Atnm-400 a Novel Non-Psma Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

THOMSON REUTERS
·
27 Mar

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

PR Newswire
·
27 Mar

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

PR Newswire
·
26 Mar

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Actinium Pharmaceuticals: Promising Clinical Advancements and Strong Financial Outlook Support Buy Rating

TIPRANKS
·
25 Mar

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

PR Newswire
·
25 Mar

Eckert & Ziegler To Supply Actinium Pharmaceuticals With AC-225 For Comprehensive Development Activities

Reuters
·
25 Mar

Actinium Pharmaceuticals Signs Actinium-225 Supply Deal With Eckert & Ziegler

MT Newswires Live
·
25 Mar

BRIEF-Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities

Reuters
·
25 Mar